Editorial board member Peter J Barnes (Imperial College, London, UK) discusses the rationale and findings of the late-breaking presentation he was involved with entitled: Risk of a severe exacerbation following higher reliever use: post-hoc analysis of SYGMA-1 in mild asthma.
1. What are the limitations of current reliever medications for mild asthma? (0:12)
2. What were the rationale for and objectives of the SYGMA-1 study? (0:47)
3. What were the findings of the recent post-hoc analysis of SYGMA-1? (2:01)
4. What are the next steps in the clinical development of the budesonide/formoterol Turbuhaler? (3:02)
5. What developments in asthma management have excited you most in the last year? (3:57)
Speaker disclosure: Peter J Barnes has received research funding from AstraZeneca and Boehringer Ingelheim and has been on advisory boards and given lectures for AstraZeneca, Boehringer Ingelheim, Chiesi, Novartis and Teva Pharmaceutical Industries Ltd.
Filmed at the European Respiratory Society (ERS) International Congress 2018, Paris, France, September 2018.
Share this Video
Related Videos In Asthma
Barbara Yawn, CHEST 2022: The role of respiratory specialists in herpes zoster vaccination
Herpes Zoster (HZ) infection is a vaccine-preventable disease that occurs when a previous infection with varicella-zoster virus (VZV) is reactivated; patients with chronic obstructive pulmonary disease (COPD) and asthma have suppressed immunity and therefore are at a higher risk of being infected and experiencing complications. We caught up with Dr. Barbara Yawn (University of Minnesota, […]
Barbara Yawn, CHEST 2022: Herpes zoster vaccination in people with asthma or chronic obstructive pulmonary disease
Herpes Zoster (HZ) infection is a vaccine-preventable disease that occurs when a previous infection with varicella-zoster virus (VZV) is reactivated; patients with chronic obstructive pulmonary disease (COPD) and asthma have suppressed immunity and therefore are at a higher risk of being infected and experiencing complications. touchRESPIRATORY were delighted to speak with Dr. Barbara Yawn (University […]
Cristiano Caruso, ERS 2022: 2 Year Findings from the REALITI-A Study of Mepolizumab in Severe Asthma
REALITI-A was an international, prospective, observational cohort study, investigating the real-world corticosteroid-sparing effect of mepolizumab in severe asthma. touchRESPIRATORY caught up with Dr. Cristiano Caruso (Columbus Hospital, Fondazione Policlinico A. Gemelli, IRCCS, Rome, Italy) to discuss the aims, design, eligibility criteria and the 2 year findings from REALITI-A. The abstract ‘International, prospective study of mepolizumab […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!